Cite
HARVARD Citation
Wang, R. et al. (2019). Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5‐Year Follow‐up. Oncologist. pp. e646-e652. [Online].